Discovery is our Business (Charles B. Huggins)
Collaborators
A well-established collaboration is essential in delivering a successful research project.
We know that scientific (or academic) research requires a diverse set of skills and capabilities, and that these skills and capabilities are essential to make our research impactful and innovative.
Find out more about our greatest collaborators below.
Senior Lecturer in Bioscience, Brunel University London
Concetta is a very talented scientist and one of the long-standing collaborators of our group. She is very skilled in the shRNA study design and preparation using cutting edge technologies such as the powerful lentiviral shRNA-mediated gene silencing. She has actively collaborated with us and continue to do so in the development of resources, tools and ideas that are the foundation of our current studies. Together we are developing the growing knowledge of PARP14 in health and disease in the search of ways for inhibiting its abnormal function in malignant cells.
Associate Professor, King's College London and Medical University of South Carolina
Wing has been a great friend and collaborator in recent years. He is a physician-scientist that has a strong track record in the search of novel treatment for GI-disease, liver fibrosis, metabolic disease and cancer. He has received post-doctoral training in the laboratory of Professor Anna Mae Diehl, Chief of Gastroenterology at Duke University. Wing and I have co-authored many publications and research abstracts.
Professor in Cancer Pathology, University of Leeds
I have known Reuben from not very long time, but he has soon shown the fine character of being experienced and trustworthy. He will provide us with access to an unparalleled resource of clinical material via the Haematological Malignancy Diagnostic Service of Leeds Teaching Hospitals NHS Trust, the leading diagnostic centre for blood cancers including myeloma in the UK. He has specific research interest in plasma cell biology and will provide our group with access to unique resources for evaluating primary normal human plasma cells under a range of conditions.
Managing Director, Innovamol srls
Dr Albeto Del Rio is an experienced medicinal chemist who led many projects on developing peptide inhibitors of tumor promoting factors for cancer treatment (i.e. Sirt6, SMYD3). His extensive expertise gained at Institute of Organic Synthesis and Photoreactivity at the National Research Council in Italy has led him to establish also a spin-off company, Innovamol, specializing in in-silico analyses and chemical experimental design.
More info can be found at http://www.innovamol.com/index.php/en/
Professor of Molecular Medicine, The Astbury Centre for Structural Molecular Biology, University of Leeds
We have recently started a collaboration with Bayliss's team to study interactions of proteins using structural, cell, chemical and computational biology approaches. We work towards understanding the molecular mechanisms that underpin cellular functions and how these events are altered in diseases such as cancer
Professor Chris Twelves
Professor of Clinical Cancer Pharmacology and Oncology, University of Leeds
Professor Chris Twelves is a professor of Clinical Cancer Pharmacology and Oncology in the St James Institute of Oncology at the University of Leeds where his research portfolio focuses on experimental cancer medicine trials, especially those incorporating pharmacologic and other translational studies.